MDT-1118 Japan DT Study

NCT ID: NCT03884504

Last Updated: 2022-10-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-05-01
• Study Completion Date: 2022-10-19

Brief Summary

To evaluate the safety and effectiveness of the MDT-1118 VAD in a patient population for destination therapy (long term support) of advanced heart failure. The collected data will be used to support Japan regulatory application in expanding market approval for destination therapy.

Conditions

Heart Failure

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Ventricular Assist Device System

Ventricular Assist Device System

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Must be ≥20 years of age at consent

2. In judgment of body size, body surface area (BSA) and anatomy by Investigator, patient can be implanted MDT-1118 VAD.

3. Patients with advanced heart failure symptoms (Class IIIB or IV) who are: (patient must meet one of the following)

1. On optimal medical management, including dietary salt restriction and diuretics, for at least 45 out of the last 60 days and are failing to respond; or

2. In Class III or Class IV heart failure for at least 14 days, and dependent on intra-aortic balloon pump (IABP) for 7 days and/or inotropes for at least 14 days

4. Left ventricular ejection fraction ≤ 25%

5. LVAD implant is intended as destination therapy

6. Must be able to receive the MDT-1118 VAD

7. Female patients of childbearing potential must agree to use adequate contraceptive precautions (defined as oral contraceptives, intrauterine devices, surgical contraceptives or a combination of condom and spermicide) for the duration of the study

8. The patient has signed the informed consent form and advance directive

9. The patient and the family understand that destination therapy is end-of-life medical care.

Exclusion Criteria

1. Patients with INTERMACS profile 1

2. Existence of any ongoing mechanical circulatory support (MCS) other than an intra-aortic balloon pump (IABP)

3. Prior cardiac transplant

4. History of confirmed, untreated abdominal/ thoracic aortic aneurysm > 5 cm, or cardiac aneurysm or intraventricular septum rupture

5. Severe calcification in thoracic aorta

6. Cardiothoracic surgery within 14 days of implantation

7. Acute myocardial infarction within 14 days of implant as diagnosed by ST or T wave changes on the ECG, diagnostic biomarkers, ongoing pain and hemodynamic abnormalities as described in the guidelines published in ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction1

8. Patients eligible for cardiac transplantation

9. On ventilator support for > 72 hours within the four days immediately prior to implantation

10. Pulmonary embolus within 21 days of implantation as documented by computed tomography (CT) scan or magnetic resonance imaging (MRI)

11. Symptomatic cerebrovascular disease, stroke within 180 days of implantation or > 80% stenosis of carotid or cranial vessels

12. Patient seems difficult to control device by oneself due to cerebral disorder

13. History of drug intoxication or alcohol dependence

14. Uncorrected moderate to severe aortic insufficiency. Correction may include repair or bioprosthesis at the time of implant

15. Severe right ventricular failure as defined by the anticipated need for right ventricular assist device (RVAD) support or extracorporeal membrane oxygenation (ECMO) at the time of screening or right atrial pressure > 20 mmHg on multiple inotropes or right ventricular ejection fraction (RVEF) <15% with clinical signs of severe right heart failure (e.g. Lower extremity edema, ascites or pleural effusions refractory to treatment with diuretics and two inotropic drugs)

16. Active, uncontrolled infection diagnosed by a combination of clinical symptoms and laboratory testing, including but not limited to, continued positive cultures, elevated temperature and white blood cell (WBC) count, hypotension, tachycardia, generalized malaise despite appropriate antibiotic, antiviral or antifungal treatment

17. Uncorrected thrombocytopenia or generalized coagulopathy (e.g., platelet count < 75,000, INR > 2.0 or PTT > 2.5 times control in the absence of anticoagulation therapy)

18. Intolerance to anticoagulant or antiplatelet therapies or any other peri- or postoperative therapy that the investigator may administer based upon the patient's health status

19. Serum creatinine > 3.0 mg/dL within 72 hours of implantation or requiring dialysis or ultrafiltration

20. Specific liver enzymes [AST (SGOT) and ALT (SGPT] > 3 times upper limit of normal within 72 hours of implantation

21. A total bilirubin > 3 mg/dL within 72 hours of implantation, or biopsy proven liver cirrhosis or portal hypertension

22. Patients with a mechanical heart valve

23. Etiology of heart failure is due to, or associated with, uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, active myocarditis or restrictive cardiomyopathy

24. History of severe COPD or severe restrictive lung disease (e.g FEV1 <50%) or severe pulmonary hypertension

25. Participation in any other study involving investigational drugs or devices

26. Severe illness, other than heart disease, which would limit survival to < 3 years

27. Peripheral vascular disease with rest pain or ischemic ulcers of the extremities

28. Pregnancy

29. Patient unwilling or unable to comply with study requirements

30. Technical obstacles, which pose an inordinately high surgical risk, in the judgment of the investigator

31. Inadequate family/social support

32. Systemic disease including collagen disease, insulin dependent severe diabetes or irreversible multi-organ failure.

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medtronic Cardiac Rhythm and Heart Failure

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

University of Tokyo

Tokyo, , Japan

Countries

Japan

Other Identifiers

MDT18052

Identifier Type: -

Identifier Source: org_study_id